A new study by R&D at British American Tobacco found that switching to exclusive use of glo resulted in significant reductions in exposure to toxicants and indicators of potential harm compared to continuing to smoke. The study showed similar reductions in biomarkers as those who stopped smoking completely.
A recent study published in Drug and Chemical Toxicology found that BAT's modern oral nicotine pouches have a comparable toxicant profile to NRTs, with significantly lower levels of toxicants than traditional oral snus. The study suggests that MO products should be placed close to NRTs on the reduced-risk product continuum.
The study shows that switching to high-quality vaping products reduces health risks and provides an alternative for smokers who would not otherwise quit. The review also emphasizes the importance of consistent product manufacturing regulations and robust stewardship standards.
The COVID-19 vaccine candidate, KBP-COVID-19, has demonstrated potential advantages in production speed and stability at room temperature, which could reduce the time between virus identification and vaccine deployment. The Phase I study will enroll 180 healthy volunteers to assess the safety and efficacy of the vaccine.
The study shows Vype ePen 3 is superior to Vype ePen 2 for nicotine delivery and ranked significantly higher in user satisfaction. The device scored nearly double the likability compared to its predecessor, with improved design features such as increased power and protonated nicotine.
A year-long study found that smokers switching exclusively to glo reduced exposure to certain toxicants, similar to quitting completely. Glo's design minimizes ash production and odour, potentially reducing smoking-related diseases risk.
New research by British American Tobacco indicates that modern oral nicotine products (MOPs) are less biologically active than traditional cigarettes and snus, with some products failing to elicit a biological response. The study suggests MOPs may be a reduced-risk option for users who switch completely from smoking.
A new vapour product called iSwitch has been shown to have significantly fewer and lower levels of certain toxicants compared to cigarette smoke. The study found that the iSwitch vapour contained no or extremely low levels of analytes, even when used at high power settings.
A new study by British American Tobacco found that vapour and tobacco heating products emit significantly fewer harmful constituents than cigarette smoke. The study analyzed actual consumer usage, finding reduced exposure to toxicants with lower consumption rates.
Researchers at British American Tobacco found that aerosols from vapour products and THPs caused significantly less staining on tooth enamel, skin, cloth, and wallpaper than cigarette smoke. The study suggests switching to these products may offer cosmetic benefits for consumers.
A year-long randomized controlled study is being conducted to evaluate the impact of switching from cigarettes to glo on markers of smoking-related disease development. The study aims to observe any favorable changes and determine if THPs may provide a less risky alternative to cigarette smoking.
The novel vaping product produced greatly reduced mutagenicity and cytotoxicity compared to cigarette smoke. Further studies are required to substantiate its potential as a reduced-risk product.
A recent study by British American Tobacco found that e-cigarettes and tobacco heating products significantly reduce enamel discoloration compared to conventional cigarettes. The researchers assessed the impact of these products on teeth using an in vitro study and found minimal staining.
A recent study published by British American Tobacco found that vaping does not cause the same level of tooth discoloration as smoking. The research used cow's teeth to test the impact of e-cigarette vapour and tobacco-heated products on tooth colour, with surprising results.
A new study shows that airway cells damaged by cigarette smoke can be reversed when exposed to glo vapour. The results suggest that glo may have reduced risk compared to conventional cigarettes.
A clinical study by British American Tobacco found that switching to glo significantly reduces exposure to cigarette smoke toxicants. The results indicate that glo vapour has lower levels of toxicants than cigarette smoke.
Scientists found that glo vapour triggered only two gene changes in human airway tissue, whereas cigarette smoke caused thousands of changes. This suggests glo vapour may cause less damage to cells compared to smoking conventional cigarettes.
New research by British American Tobacco finds that vapour from gloTM has no toxic effect on human lung cells, unlike cigarette smoke. The study's results indicate that gloTM is substantially less harmful and may be considered a reduced-risk alternative.
Scientists found gloTM vapour produces significantly lower levels of harmful compounds compared to cigarette smoke. The study measured 126 substances and found that 102 were emitted 95% less in gloTM vapour than in cigarette smoke.
Scientists ranked glo™ and other next-generation products against conventional cigarettes, finding reduced toxicants in vapour and biological impact on cells. Glo™ produced a substantially reduced response compared to cigarette smoke.
The Vype ePen database presents comprehensive scientific test results, showing the product has a lower toxicity profile than traditional cigarettes. Clinical and population studies indicate efficient nicotine delivery, reducing harm and increasing quit rates.
Scientists have identified two mutated genes associated with nitrogen utilization in tobacco, which could lead to the development of plants requiring less nitrogen and reduced levels of carcinogenic compounds in cigarette smoke. This discovery has significant implications for sustainable agriculture and reducing environmental pollution.
A laboratory study reveals that e-cigarette vapour has no effect on wound healing, whereas cigarette smoke completely prevents it at concentrations over 20%. The test used the scratch test to compare the effects of smoke extract and vapour extract from two commercial e-cigarettes.
A study found that vapour from a novel hybrid tobacco heating product and two standard THPs had little to no impact on human cells in lab-based biological tests. The results suggest these products could reduce smoking-related disease risks when compared to cigarette smoking.
A new tobacco hybrid device, iFuse, produces a vapour with similar toxicant profile to e-cigarette Vype ePen, but with enhanced flavour. The vapour's toxicity levels are significantly lower than those in cigarette smoke.
Research by British American Tobacco found that e-cigarette vapour has a limited effect on gene expression in human lung cells compared to cigarette smoke. The study exposed MucilAir 3D models to equivalent or higher doses of nicotine and measured the genes affected, revealing significant differences in response.
A new predictive model developed by British American Tobacco predicts that e-cigarettes will help reduce smoking prevalence in the UK to 9.7% by 2050. The model takes into account various scenarios and factors, including consumer behavior, demographics, and health effects, and suggests a significant reduction in smoking-related deaths.
Citric acid's thermal degradation can form anhydrides, which are known to trigger allergic reactions. Researchers warn that these chemicals could be released in e-cigarette vapor, posing health risks.
E-cigarette vapour exposure has been shown to be genotoxic and cytotoxic in human lung cells at high doses. In contrast, Vype e-cigarette vapour produced no DNA damage even at 28 times the equivalent smoke dose. The findings suggest that e-cigarettes are safer than smoking cigarettes.
Researchers used smoking/vaping robots to study e-cigarette aerosol's effect on human lung cells. The results show that e-cigarette aerosol is effectively delivered to cell surfaces, despite having a reduced biological impact compared to cigarette smoke.
E-cigarettes are effective at delivering nicotine, particularly for experienced users. The study found that newer generation e-cigarettes outperform first-generation devices in terms of nicotine delivery. However, the efficacy of e-cigarettes also depends on individual behavior and vaping habits.
The need for a bridging regulatory mechanism is highlighted in e-cigarette innovations; reducing the burden on regulators while maintaining product development. A reduced data set for initial products and focused tests for variants can support this process.
In a lab-based test using the Ames assay, scientists found that e-cigarette vapour did not cause DNA mutations in bacteria, unlike tobacco smoke. The results suggest that e-cigarettes may be less harmful than cigarettes, supporting growing evidence of their potential as a safer alternative.
A new study using a modified Smoking Analyser technology examines vaping behaviour in e-cigarette users. The results provide valuable insights into how vapers use e-cigarettes and can help establish standardized testing protocols for e-cigarette emissions.
Lab tests reveal e-cigarette vapor is non-toxic to human lung cells, even at unrealistically high doses. Cigarette smoke proves cytotoxic, with lung cells showing low levels of toxicity only after equivalent daily exposure in just one hour.
Lab tests reveal e-cigarette vapor does not cause oxidative stress and cell death in lung epithelial cells, unlike cigarette smoke. Researchers developed a standardized method to compare the effects of conventional cigarette smoke and e-cigarette vapor on lung cells.
A recent study by British American Tobacco found that e-cigarette vapour contains toxicant levels on average 95% lower than conventional cigarette smoke. The study measured 142 compounds in e-cigarette vapour and found substantial reductions in toxicant groups, with most cigarette smoke toxicants undetectable.
The development of global standards for vaping products is essential to promote innovation and protect consumers. Different regulatory approaches in the EU and US can hinder growth and stifle innovation, as noted by British American Tobacco's Head of R&D, Marina Trani.
In vitro tests of Vype ePen e-cigarette vapor revealed no activation of cell stress responses, DNA damage, or cellular transformation. In contrast, cigarette smoke induced significant DNA damage and promoted tumour formation in human lung cells.
A novel hybrid product called 'glo iFUSE' combines e-cigarette technology with fresh tobacco to deliver natural tobacco flavors. Sensory testing confirmed the presence of detectable tobacco flavors, and chemical analysis revealed a significant reduction in toxic compounds compared to traditional cigarettes.
A new study found that daily e-cigarette formaldehyde exposure from three formats is well below the World Health Organization's safe levels. The results showed that even heavy use of these products still only results in daily formaldehyde exposure less than one-sixth of indoor air quality standards.
Scientists at British American Tobacco have proposed a new assessment framework for innovative nicotine and tobacco products. The four-stage process evaluates lab-based testing, clinical trials, real-world observations, and individual and population perception.
A comprehensive assessment of acrylamide in smokeless tobacco products found exposure levels to be relatively low and comparable across different types. However, the study suggests that snus and other STPs present a minor source of acrylamide exposure compared to diet or cigarette smoking.
Researchers used a unique combination of tests to investigate the potential adverse effects of e-cigarette vapour on airway tissue. The results show that despite six hours of exposure, the impact of e-cigarette vapour on airway tissue is similar to that of air.
A new guide provides a systematic approach to evaluating the safety of e-cig flavorings, considering toxicological thresholds and thermal breakdown products. The guide aims to fill data gaps and provide guidance for regulatory standards, ensuring safer e-cigarette production.
Researchers at British American Tobacco developed a new smoking-specific survey, TQoLIT, to assess the impact of next-generation tobacco and nicotine products on 'otherwise healthy' smokers. The tool improves upon existing general health questionnaires by reducing ceiling effects and detecting specific smoking-related health changes.
A new human respiratory tissue model, MucilAir, has been shown to maintain normal biochemical processes for at least six months. The model is suitable for testing the impact of repeated exposures over a prolonged period, making it a valuable tool for assessing the toxicological effects of inhaled chemicals and safety of medicines.
A comprehensive survey of toxicants in smokeless tobacco products found that hydrazine is not a prevalent contaminant. Trace levels were detected in some samples but significantly lower than previous reports.
A suite of globally harmonized test methods is needed to measure a wider selection of toxicants in cigarette smoke. The International Organization for Standardization (ISO) must coordinate these methods to ensure reproducible and comparable results.
A new study by British American Tobacco found that slim cigarette smokers experience lower exposure to toxic chemicals like carbon monoxide and acetaldehyde. The researchers attribute this reduction to the smaller size of slim cigarettes, making it harder for smokers to draw on.